S&P 500   3,132.65 (-0.11%)
DOW   27,864.21 (-0.16%)
QQQ   203.93 (-0.07%)
AAPL   267.13 (+0.08%)
FB   201.72 (+0.19%)
MSFT   151.07 (-0.19%)
GOOGL   1,339.31 (-0.27%)
AMZN   1,745.16 (-0.25%)
CGC   21.19 (-0.47%)
NVDA   212.43 (+0.12%)
MU   47.17 (+1.53%)
BABA   200.05 (+0.66%)
GE   10.95 (-0.36%)
TSLA   341.02 (+0.44%)
T   37.98 (-0.16%)
AMD   38.99 (+0.15%)
ACB   2.62 (+0.00%)
F   9.00 (-0.22%)
PRI   135.47 (+0.09%)
NFLX   296.47 (-1.99%)
BAC   33.36 (-0.45%)
GILD   66.58 (-0.52%)
DIS   145.60 (-0.42%)
S&P 500   3,132.65 (-0.11%)
DOW   27,864.21 (-0.16%)
QQQ   203.93 (-0.07%)
AAPL   267.13 (+0.08%)
FB   201.72 (+0.19%)
MSFT   151.07 (-0.19%)
GOOGL   1,339.31 (-0.27%)
AMZN   1,745.16 (-0.25%)
CGC   21.19 (-0.47%)
NVDA   212.43 (+0.12%)
MU   47.17 (+1.53%)
BABA   200.05 (+0.66%)
GE   10.95 (-0.36%)
TSLA   341.02 (+0.44%)
T   37.98 (-0.16%)
AMD   38.99 (+0.15%)
ACB   2.62 (+0.00%)
F   9.00 (-0.22%)
PRI   135.47 (+0.09%)
NFLX   296.47 (-1.99%)
BAC   33.36 (-0.45%)
GILD   66.58 (-0.52%)
DIS   145.60 (-0.42%)
S&P 500   3,132.65 (-0.11%)
DOW   27,864.21 (-0.16%)
QQQ   203.93 (-0.07%)
AAPL   267.13 (+0.08%)
FB   201.72 (+0.19%)
MSFT   151.07 (-0.19%)
GOOGL   1,339.31 (-0.27%)
AMZN   1,745.16 (-0.25%)
CGC   21.19 (-0.47%)
NVDA   212.43 (+0.12%)
MU   47.17 (+1.53%)
BABA   200.05 (+0.66%)
GE   10.95 (-0.36%)
TSLA   341.02 (+0.44%)
T   37.98 (-0.16%)
AMD   38.99 (+0.15%)
ACB   2.62 (+0.00%)
F   9.00 (-0.22%)
PRI   135.47 (+0.09%)
NFLX   296.47 (-1.99%)
BAC   33.36 (-0.45%)
GILD   66.58 (-0.52%)
DIS   145.60 (-0.42%)
S&P 500   3,132.65 (-0.11%)
DOW   27,864.21 (-0.16%)
QQQ   203.93 (-0.07%)
AAPL   267.13 (+0.08%)
FB   201.72 (+0.19%)
MSFT   151.07 (-0.19%)
GOOGL   1,339.31 (-0.27%)
AMZN   1,745.16 (-0.25%)
CGC   21.19 (-0.47%)
NVDA   212.43 (+0.12%)
MU   47.17 (+1.53%)
BABA   200.05 (+0.66%)
GE   10.95 (-0.36%)
TSLA   341.02 (+0.44%)
T   37.98 (-0.16%)
AMD   38.99 (+0.15%)
ACB   2.62 (+0.00%)
F   9.00 (-0.22%)
PRI   135.47 (+0.09%)
NFLX   296.47 (-1.99%)
BAC   33.36 (-0.45%)
GILD   66.58 (-0.52%)
DIS   145.60 (-0.42%)
Log in

NASDAQ:MITI - Amgen Rockville Stock Price, Forecast & News

Notice: This company has been marked as potentially delisted and may not be actively trading.
Add
Today's Range N/A
50-Day Range N/A
52-Week Range N/A
VolumeN/A
Average VolumeN/A
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Designs and develops antibody-based drugs for treatment of cancer. The Company is a biotechnology company with a focus on the development of antibody-based products for cancer and inflammatory and autoimmune diseases. Micromet has established a drug development platform based on its BiTE technology, a drug format that leverages the cytotoxic potential of T cells.

Industry, Sector and Symbol

Industry N/A
Sub-IndustryN/A
SectorN/A
Current SymbolNASDAQ:MITI
CUSIPN/A
Phone+1-240-7521420

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

EmployeesN/A
Next Earnings DateN/A
OptionableNot Optionable

Receive MITI News and Ratings via Email

Sign-up to receive the latest news and ratings for MITI and its competitors with MarketBeat's FREE daily newsletter.


Amgen Rockville (NASDAQ:MITI) Frequently Asked Questions

What is Amgen Rockville's stock symbol?

Amgen Rockville trades on the NASDAQ under the ticker symbol "MITI."

Has Amgen Rockville been receiving favorable news coverage?

News headlines about MITI stock have been trending negative recently, according to InfoTrie. The research group identifies negative and positive press coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Amgen Rockville earned a coverage optimism score of -2.0 on InfoTrie's scale. They also gave press coverage about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the stock's share price in the immediate future. View News Stories for Amgen Rockville.

What is Amgen Rockville's official website?

The official website for Amgen Rockville is http://www.micromet.com/.

How can I contact Amgen Rockville?

Amgen Rockville's mailing address is 9201 Corporate Blvd Ste 400, ROCKVILLE, MD 20850-7209, United States. The biotechnology company can be reached via phone at +1-240-7521420.


MarketBeat Community Rating for Amgen Rockville (NASDAQ MITI)

Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  99 (Vote Outperform)
Underperform Votes:  75 (Vote Underperform)
Total Votes:  174
MarketBeat's community ratings are surveys of what our community members think about Amgen Rockville and other stocks. Vote "Outperform" if you believe MITI will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MITI will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 12/10/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel